Neuromyelitis Optica clinical trials

Explore recruiting neuromyelitis optica clinical trials.

Recruiting neuromyelitis optica studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neuromyelitis Optica trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

lmlifidase treatment tor acute inflammation in AQP4-lgG associated neuromyelitis optica spectrum disorder (DEFEAT NMOSD)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects with Neuromyelitis Optica Spectrum Disorder

Spain, Poland, Sweden, Netherlands, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Multicenter, Open-Label, Uncontrolled Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients with AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Italy, France, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)

France, Italy, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

Neuromyelitis Optica trials by city

Neuromyelitis Optica in Toronto Neuromyelitis Optica in Vancouver Neuromyelitis Optica in Montreal Neuromyelitis Optica in Calgary Neuromyelitis Optica in Edmonton Neuromyelitis Optica in Ottawa Neuromyelitis Optica in Winnipeg Neuromyelitis Optica in Quebec City Neuromyelitis Optica in Hamilton Neuromyelitis Optica in Kitchener Neuromyelitis Optica in London Neuromyelitis Optica in Halifax Neuromyelitis Optica in New York Neuromyelitis Optica in Los Angeles Neuromyelitis Optica in Chicago Neuromyelitis Optica in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease